InGel Therapeutics is a regenerative cell-therapy biotech leveraging novel neuro-protective and neuro-repairing mechanisms to tackle retinal degeneration. We develop stem-cell therapeutics and biodegradable polymers to enhance and create therapies for eye diseases that cause retinal degeneration. Our beachhead indication is retinitis pigmentosa, while future expansion opportunities include dry age-related macular degeneration and glaucoma. The company's proprietary technology includes a stem cell therapy applied directly to the eye to halt retinal degeneration and vision loss, therefore restoring vision. This work was previously developed at Harvard Medical School (via Massachusetts Eye and Ear) by a team of engineers, cell biologists, and retinal specialists.